MGMT and glioma: In contrast, the clinical prognostic value of MGMT promoter methylation in grade IV gliomas remained unclear, although its significance as a predictor of treatment outcome to combined chemoirradiation with temozolamide in glioblastomas has been demonstrated in some studies [23].